A familial hypertrophic cardiomyopathy α-tropomyosin mutation causes severe cardiac hypertrophy and death in mice

Rethinasamy Prabhakar, Greg P. Boivin, Ingrid L. Grupp, Brian Hoit, Grace Arteaga, R. John Solaro, David F. Wieczorek

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Tropomyosin, an essential component of the sarcomere, regulates muscle contraction through Ca2+-mediated activation. Familial hypertrophic cardiomyopathy (FHC) is caused by mutations in numerous cardiac sarcomeric proteins, including myosin heavy and light chains, actin, troponin T and I, myosin binding protein C, and α-tropomyosin. This study developed transgenic mouse lines that encode an FHC mutation in α-tropomyosin: this mutation is an amino acid substitution at codon 180 (Glu180Gly) which occurs in a troponin T binding region. Non-transgenic and control mice expressing wildtype α-tropomyosin demonstrate no morphological or physiological changes. Expression of exogenous mutant tropomyosin leads to a concomitant decrease in endogenous α-tropomyosin without altering the expression of other contractile proteins. Histological analysis shows that initial pathological changes, which include ventricular concentric hypertrophy, fibrosis and atrial enlargement, are detected within 1 month. The disease-associated changes progressively increase and result in death between 4 and 5 months. Physiological analyses of the FHC mice using echocardiography, work-performing heart analyses, and force measurements of cardiac myofibers, demonstrate dramatic functional differences in diastolic performance and increased sensitivity to calcium. This report demonstrates that mutations in α-tropomyosin can be severely disruptive of sarcomeric function, which consequently triggers a dramatic hypertrophic response that culminates in lethality.

Original languageEnglish (US)
Pages (from-to)1815-1828
Number of pages14
JournalJournal of Molecular and Cellular Cardiology
Volume33
Issue number10
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Familial Hypertrophic Cardiomyopathy
Tropomyosin
Cardiomegaly
Mutation
Troponin T
Contractile Proteins
Myosin Light Chains
Sarcomeres
Troponin I
Myosin Heavy Chains
Amino Acid Substitution
Muscle Contraction
Codon
Hypertrophy
Transgenic Mice
Echocardiography
Actins
Fibrosis
Calcium

Keywords

  • Cardiac hypertrophy
  • Familial hypertrophic cardiomyopathy
  • Sarcomeric function
  • Transgenic mice
  • Tropomyosin

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

Prabhakar, R., Boivin, G. P., Grupp, I. L., Hoit, B., Arteaga, G., Solaro, R. J., & Wieczorek, D. F. (2001). A familial hypertrophic cardiomyopathy α-tropomyosin mutation causes severe cardiac hypertrophy and death in mice. Journal of Molecular and Cellular Cardiology, 33(10), 1815-1828. https://doi.org/10.1006/jmcc.2001.1445

A familial hypertrophic cardiomyopathy α-tropomyosin mutation causes severe cardiac hypertrophy and death in mice. / Prabhakar, Rethinasamy; Boivin, Greg P.; Grupp, Ingrid L.; Hoit, Brian; Arteaga, Grace; Solaro, R. John; Wieczorek, David F.

In: Journal of Molecular and Cellular Cardiology, Vol. 33, No. 10, 2001, p. 1815-1828.

Research output: Contribution to journalArticle

Prabhakar, Rethinasamy ; Boivin, Greg P. ; Grupp, Ingrid L. ; Hoit, Brian ; Arteaga, Grace ; Solaro, R. John ; Wieczorek, David F. / A familial hypertrophic cardiomyopathy α-tropomyosin mutation causes severe cardiac hypertrophy and death in mice. In: Journal of Molecular and Cellular Cardiology. 2001 ; Vol. 33, No. 10. pp. 1815-1828.
@article{04600d1d737a461fa1c2e294ca912bf1,
title = "A familial hypertrophic cardiomyopathy α-tropomyosin mutation causes severe cardiac hypertrophy and death in mice",
abstract = "Tropomyosin, an essential component of the sarcomere, regulates muscle contraction through Ca2+-mediated activation. Familial hypertrophic cardiomyopathy (FHC) is caused by mutations in numerous cardiac sarcomeric proteins, including myosin heavy and light chains, actin, troponin T and I, myosin binding protein C, and α-tropomyosin. This study developed transgenic mouse lines that encode an FHC mutation in α-tropomyosin: this mutation is an amino acid substitution at codon 180 (Glu180Gly) which occurs in a troponin T binding region. Non-transgenic and control mice expressing wildtype α-tropomyosin demonstrate no morphological or physiological changes. Expression of exogenous mutant tropomyosin leads to a concomitant decrease in endogenous α-tropomyosin without altering the expression of other contractile proteins. Histological analysis shows that initial pathological changes, which include ventricular concentric hypertrophy, fibrosis and atrial enlargement, are detected within 1 month. The disease-associated changes progressively increase and result in death between 4 and 5 months. Physiological analyses of the FHC mice using echocardiography, work-performing heart analyses, and force measurements of cardiac myofibers, demonstrate dramatic functional differences in diastolic performance and increased sensitivity to calcium. This report demonstrates that mutations in α-tropomyosin can be severely disruptive of sarcomeric function, which consequently triggers a dramatic hypertrophic response that culminates in lethality.",
keywords = "Cardiac hypertrophy, Familial hypertrophic cardiomyopathy, Sarcomeric function, Transgenic mice, Tropomyosin",
author = "Rethinasamy Prabhakar and Boivin, {Greg P.} and Grupp, {Ingrid L.} and Brian Hoit and Grace Arteaga and Solaro, {R. John} and Wieczorek, {David F.}",
year = "2001",
doi = "10.1006/jmcc.2001.1445",
language = "English (US)",
volume = "33",
pages = "1815--1828",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",
number = "10",

}

TY - JOUR

T1 - A familial hypertrophic cardiomyopathy α-tropomyosin mutation causes severe cardiac hypertrophy and death in mice

AU - Prabhakar, Rethinasamy

AU - Boivin, Greg P.

AU - Grupp, Ingrid L.

AU - Hoit, Brian

AU - Arteaga, Grace

AU - Solaro, R. John

AU - Wieczorek, David F.

PY - 2001

Y1 - 2001

N2 - Tropomyosin, an essential component of the sarcomere, regulates muscle contraction through Ca2+-mediated activation. Familial hypertrophic cardiomyopathy (FHC) is caused by mutations in numerous cardiac sarcomeric proteins, including myosin heavy and light chains, actin, troponin T and I, myosin binding protein C, and α-tropomyosin. This study developed transgenic mouse lines that encode an FHC mutation in α-tropomyosin: this mutation is an amino acid substitution at codon 180 (Glu180Gly) which occurs in a troponin T binding region. Non-transgenic and control mice expressing wildtype α-tropomyosin demonstrate no morphological or physiological changes. Expression of exogenous mutant tropomyosin leads to a concomitant decrease in endogenous α-tropomyosin without altering the expression of other contractile proteins. Histological analysis shows that initial pathological changes, which include ventricular concentric hypertrophy, fibrosis and atrial enlargement, are detected within 1 month. The disease-associated changes progressively increase and result in death between 4 and 5 months. Physiological analyses of the FHC mice using echocardiography, work-performing heart analyses, and force measurements of cardiac myofibers, demonstrate dramatic functional differences in diastolic performance and increased sensitivity to calcium. This report demonstrates that mutations in α-tropomyosin can be severely disruptive of sarcomeric function, which consequently triggers a dramatic hypertrophic response that culminates in lethality.

AB - Tropomyosin, an essential component of the sarcomere, regulates muscle contraction through Ca2+-mediated activation. Familial hypertrophic cardiomyopathy (FHC) is caused by mutations in numerous cardiac sarcomeric proteins, including myosin heavy and light chains, actin, troponin T and I, myosin binding protein C, and α-tropomyosin. This study developed transgenic mouse lines that encode an FHC mutation in α-tropomyosin: this mutation is an amino acid substitution at codon 180 (Glu180Gly) which occurs in a troponin T binding region. Non-transgenic and control mice expressing wildtype α-tropomyosin demonstrate no morphological or physiological changes. Expression of exogenous mutant tropomyosin leads to a concomitant decrease in endogenous α-tropomyosin without altering the expression of other contractile proteins. Histological analysis shows that initial pathological changes, which include ventricular concentric hypertrophy, fibrosis and atrial enlargement, are detected within 1 month. The disease-associated changes progressively increase and result in death between 4 and 5 months. Physiological analyses of the FHC mice using echocardiography, work-performing heart analyses, and force measurements of cardiac myofibers, demonstrate dramatic functional differences in diastolic performance and increased sensitivity to calcium. This report demonstrates that mutations in α-tropomyosin can be severely disruptive of sarcomeric function, which consequently triggers a dramatic hypertrophic response that culminates in lethality.

KW - Cardiac hypertrophy

KW - Familial hypertrophic cardiomyopathy

KW - Sarcomeric function

KW - Transgenic mice

KW - Tropomyosin

UR - http://www.scopus.com/inward/record.url?scp=0034781383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034781383&partnerID=8YFLogxK

U2 - 10.1006/jmcc.2001.1445

DO - 10.1006/jmcc.2001.1445

M3 - Article

VL - 33

SP - 1815

EP - 1828

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

IS - 10

ER -